The
Amount of "Rigorous Research" About This Topic

3Extensive Research: Numerous high-quality, scientific studies
have been done, including clinical trials and other research published in major
peer-reviewed journals. Reliable scientific information is available.
2Some Research: Some good quality, scientific studies have been
published in peer-reviewed journals. Some reliable scientific information is available.
1Limited Research: A small number of scientific studies have
been done, but few have been published in peer-reviewed journals. Some scientific
information may be available.
0No Research: No scientific studies have been done. No
scientific information is available.
Notes:
The above levels of research are based on the amount of published, rigorous clinical
research conducted or sponsored by the NCCAM, other Institutes and Centers of the NIH, and
other biomedical research institutions in the United States and internationally.
Treatments described in this publication are experimental. Always discuss any new
treatment options with your health care provider.
More information about the levels of science listed above. |
|
Introduction
Hepatitis C is a serious communicable (contagious) disease of the liver that is caused
by the hepatitis C virus (HCV). Hepatitis C and its implications were identified only
recently. There still is much to learn about the disease, the virus that causes it, and
treatment optionsboth conventional and alternative.
About 3 million Americans are infected with HCV, and many of them do not even know they
have it. Other forms of viral hepatitis usually resolve without treatment. But most people
with HCV85 percentdevelop chronic (frequent or long-lasting) hepatitis C. The
majority of people infected with HCV show no symptoms for up to 20 to 30 years. During
that time, though, the infection may be slowly damaging the person's liver.
The virus can be found in a number of organs of the body. However, the infection is
spread mainly by contact with the blood of an infected person. Once a person is infected,
the body's immune (disease-fighting) system cannot combat the virus very well.
Most people with chronic hepatitis C develop long-term liver disease, which interferes
with the liver's ability to work properly. Some patients eventually develop cirrhosis
(scarring of the liver); some get liver cancer; and some even die from liver disease.
Repeated injections of regular ("conventional") drugs, like interferon,
currently available to treat chronic hepatitis C get rid of the virus only in
approximately 30 to 40 percent of infected people. In addition, these drugs can produce
unbearable side effects. So, many people are looking to complementary and alternative
therapies for help.
No complementary medicine or alternative medicine therapies have been scientifically
proven to cure or even ease symptoms of hepatitis C.
However, some people are turning to herbs for relief. They use herbs either to help
with hepatitis itself or to deal with side effects of interferon. These harmful side
effects can include: sudden hearing loss; anemia and other forms of low blood cell counts;
headaches; heart, eye, liver, or kidney problems; and disorders of the mind, including
depression. Among potential herbal therapies (including licorice root, ginseng, ginger,
and St. John's wort) for hepatitis C, the most promising alternative treatment seems to be
the herb commonly called milk thistle.
Preliminary studies in animals show that milk thistle may help protect the liver from
injury by a variety of toxins ("poisons" such as drugs, viruses, alcohol,
radiation, and poisonous mushrooms) and limit the damage from them.1,2 To date, the most reliable, and also quite preliminary, studies on
people show that milk thistle does not cure liver disease, but that it may improve the way
the liver works in patients with cirrhosis.1 However, there
is no current evidence to indicate that milk thistle directly affects HCV.
In Germany, where many herbs are regulated and prescribed like drugs, health
authorities have approved milk thistle as a complementary treatment (given in addition to
conventional drugs) for cirrhosis, hepatitis, and similar liver conditions.2
But a great deal of research still is needed before this alternative therapy could be
considered a standard treatment option in the United States.
Milk thistle originally is from Europe, but now it also is grown in the United States.
Its scientific name is Silybum marianum. The ingredient that experts believe is
responsible for its medicinal qualities is called silymarin. Silymarin is found in the
fruits of the milk thistle plant. Studies in animals have shown that this active
ingredient promotes the following activities:
Liver Cell GrowthSilymarin appears to promote the growth of some
types of cells in the liver.1,2
AntioxidationSilymarin may be an effective
"antioxidant," which means it may help fight a destructive chemical process in
the body known as "oxidation." In oxidation, harmful substances produced in the
body (called free radicals) can damage cells. Some studies suggest that silymarin can
prevent these substances from damaging liver cells.1,3,4
Antihepatotoxic ActivityStudies suggest that silymarin can block
various types of toxins from entering and injuring liver cells.1,2,5
Inflammation InhibitionSilymarin is thought to prevent
inflammation (swelling) of the liver; this may be described as displaying
anti-inflammatory properties.1
Milk thistle is not used to prevent HCV from causing liver disease. Rather, it is used
with the hope that it would minimize the damage to the liver that HCV can cause.
Although studies in animals provide a good deal of information on potential new
treatments, studies in humans are needed before it can be determined if these therapies
are appropriate, safe, and effective in people. The most rigorous type of study to
establish a scientific basis for use of a new therapy in people is a randomized,
double-blind, placebo-controlled (RDBPC) trial.
Although not focused primarily on HCV disease, the most relevant existing research data
regarding milk thistle's use as a therapy for hepatitis comes from two RDBPC trials of
silymarin's effects on cirrhosis.1 The two studies produced
conflicting results.
The first, reported in 1989, examined 170 patients with cirrhosis from various causes,
including alcohol abuse.6 Approximately half (87) of
the patients received silymarin (140 milligrams 3 times a day for 2 years). The others (83
patients) received a placebo. Because 24 patients dropped out of the study, a total of 146
patients (73 in each group) finished the 2-year study.
The doctors in this study noted that the number of patients who died in the 4 years
after the study was 31 percent lower in the group that received the silymarin than in the
group of patients who received the placebo. The beneficial effects of silymarin were
especially seen in the patients who had cirrhosis as a result of alcohol abuse. The
doctors did not report that any patients experienced side effects from silymarin
treatment.
A more recent RDBPC trial, however, did not find silymarin to have any significant
benefits for patients with cirrhosis.7 In this study,
reported in 1998, doctors examined 200 patients with cirrhosis caused by alcohol abuse.
Approximately half (103) of the patients received silymarin (150 milligrams 3 times a day
for 2 years). The other half (97) received a placebo. A total of 125 patients (57 in the
treatment group and 68 in the placebo group) finished the 2-year study. To measure
effectiveness, the doctors measured (1) time to death and (2) the worsening of the
disease.
Survival was similar in both the silymarin and placebo groups, and silymarin did not
seem to improve the course of the disease in the treatment group. The doctors who
performed the experiment did not note side effects in any of the patients.
Although small, one randomized controlled trial on hepatitis patients suggests that a
specific component in silymarin may be beneficial in managing chronic hepatitis.8 In this study, reported in 1993, 10 patients with
chronic hepatitis were assigned to the treatment group and 10 others were assigned to the
placebo group. The treatment group received 240 milligrams of silybin, a component of
silymarin, two times a day for 1 week. The results of tests that measure how well the
liver is functioning showed significant improvement in the treatment group, suggesting
that silybin may help treat chronic hepatitis.
Milk thistle in the treatment of liver disease needs to be studied further.
Fortunately, negative side effects have not yet been reported, and this herbal therapy may
be much less expensive than conventional drug therapies. Yet, it should be mentioned that
conventional therapies have been proven to work in a substantial portion of patients.
Because milk thistle does not dissolve well in water, the herb is not effective in the
form of a tea. It currently is marketed in the United States as a dietary supplement in
the form of capsules containing 200 milligrams of a concentrated extract with 140
milligrams of silymarin.
Licorice RootHerbalists use tea made with licorice root to
manage some of the effects hepatitis has on the liver. The scientific name for licorice
root is Glycyrrhiza glabra, and its active component is called glycyrrhizin.
Studies suggest that licorice root displays antiviral and anti-inflammatory properties.9
Licorice root does come with a warning, however. If taken regularly (more than 3 grams
of licorice root a day for more than 6 weeks, or more than 100 milligrams of glycyrrhizin
a day), this herb can cause the following conditions in some people: high blood pressure,
sodium and water retention, low potassium levels in the bloodstream, and disturbance of an
important electrolyte balancing system in the body.
Signs and symptoms of excessive licorice root consumption may include headache,
sluggishness, puffiness and swollen ankles, and even heart failure or cardiac arrest (when
the heart suddenly stops beating).10
Glycyrrhizin has been used in Japan for more than 20 years as a treatment for chronic
hepatitis.9,11 In a 1998 review11 of several randomized controlled trials, researchers
reported that treatment with glycyrrhizin is effective in easing liver disease in some
people. Several of the trials reviewed indicated improvements in liver tissue that had
been damaged by hepatitis. Some of them also showed improvements in how well the liver
does its job.
A great deal of scientific research still is
needed to learn if these alternative therapies are safe and effective in people.
A 1997 experiment suggested that glycyrrhizin also may help prevent the development of
liver cancer in patients with chronic hepatitis C.12
The use of glycyrrhizin as a complementary therapy (in addition to conventional use
of interferon drugs) has been studied, but no significant benefit has been found yet.13,14
GinsengTests on animals and on human tissues suggest that
ginseng may help the body's disease-fighting and glandular systems. Tests in small animals
also suggest that ginseng may help improve the way the liver works and reduce damage to
liver tissue caused by hepatitis and similar conditions.15,16,17 However, a search of the
current literature shows no studies in people that test ginseng's helpfulness for
hepatitis. Only one study, conducted in Italy, shows that ginseng may be helpful for
elderly people with liver conditions similar to hepatitis.18
There are two true ginsengsAmerican ginseng (Panax quinquefolius) and
Asian ginseng (Panax ginseng), which includes Chinese, Japanese, and Korean
ginseng. Siberian ginseng (Eleutherococcus senticosus) is not a true ginseng.1,19 It is hard to get authentic ginseng
products. Companies that market herbs for sale have poor quality control, so the quality
of the different brands varies widely. A 1990 analysis of 54 available ginseng products
revealed that 85 percent of them contained little or no ginseng at all!19 Ginseng most often is taken as a tea.
GingerFor 2,500 years, the Chinese have used ginger (Zingiber
officinale) to treat nausea.1 Some, but not all,
research studies confirm that ginger may reduce nausea.1
This herb may relieve nausea and vomiting caused by interferon drug therapy in some
patients with hepatitis C. Ginger generally is recognized as safe and is not known to
cause any serious side effects. Ginger is relatively inexpensive and readily available. It
most commonly is taken in the form of a tea.
St. John's WortSome patients with hepatitis C take the herb St.
John's wort (Hypericum perforatum) to treat depression caused by interferon drug
therapy. Although St. John's wort is not a proven treatment for depression, studies have
shown that it does have antidepressive effects over the short term. Although research
largely has been done using capsules of this herb, St. John's wort also is taken as a tea.
There is no proof yet that St. John's wort is effective and safe over the long term.
St. John's wort does not require a prescription, and it is less expensive and may have
fewer side effects than prescription antidepressant drugs.20
Tests in people reveal it may cause side effects such as fatigue, dry mouth, dizziness,
digestive tract symptoms, and increased sensitivity to sunlight.
- Get an accurate diagnosis from your doctor. Hepatitis C infection can be diagnosed only
by using sophisticated blood tests available to all doctors.
- Tell your doctor about all of the medications you are taking, even any over-the-counter
drugs or herbs or other alternative therapies you may be using. Because the liver plays a
key role in processing drugs, alcohol, and toxins in the bloodstream, medications,
alcoholic beverages, and certain herbs can make the disease worse.
- Consider being vaccinated against hepatitis A and B.21
Unlike hepatitis A and B, previous infection with HCV does not make you immune to it in
the future.21 Infection with HCV also does not prevent
you from becoming infected with other types of hepatitis (hepatitis A, B, D, E, and G).
- Do not try to treat the disease yourself.
- Do not drink alcohol, because it can further damage your already diseased liver.
- Do not share needles if you use injection drugs.
For more information about hepatitis C, you may want to contact the following
organizations:
For more information about alternative therapies for hepatitis C, you may wish to
contact the following organizations:
For more information about complementary or alternative medicine, contact the NCCAM
Clearinghouse by telephone, mail, e-mail, or fax:
- NCCAM Clearinghouse
P.O. Box 8218
Silver Spring, MD 20907-8218
1-888-644-6226 (Toll-Free, TTY/TDY, and Fax-On-Demand)
1-301-495-4957 (Fax)
nccamc@altmedinfo.org (E-Mail)
http://nccam.nih.gov (NCCAM Web Site)
- Active Treatment
- The treatment being tested by the experiment.
- Alternative Medicine
- Medical systems, therapies, and techniques that mainstream Western (conventional)
medicine does not commonly use, accept, study, understand, or make available. Alternative
medicine includes practices usually used instead of conventional medical practices.
Alternative health care practices include a vast array of treatments and beliefs, which
may be well-known, exotic, mysterious, or even dangerous. They are based on no common or
consistent philosophy or school of thought. A few of the many alternative medicine
practices include the use of acupuncture, homeopathy, herbs, therapeutic massage, and
traditional oriental medicine to promote well-being or treat health conditions.
- Complementary Medicine
- Alternative medical systems used in conjunction with or in addition to conventional
medicine to further promote health. For example, a person may use herbal remedies to ease
some of the side effects, such as nausea, of certain conventional drugs.
- Controls
- Patients who do not receive the treatment being studied; the experimental group is
compared to the control group to objectively evaluate the treatments effectiveness.
- Double-Blind
- A type of study in which neither the participants nor the doctors giving the treatments
know who is getting the active treatment and who is getting the placebo.
- Liver
- A large gland in the upper abdomen that is essential to life. Important liver functions
include: helping the body produce or make use of the fats, sugars, proteins, vitamins, and
most other compounds it needs; and reducing the ill effects of poisons, such as alcohol
and nicotine, in the body.
- Placebo
- A presumably pharmacologically inactive or fake treatment. If in the form of
a pill, a placebo sometimes is referred to as a dummy pill or sugar
pill.
- Placebo-Controlled
- A type of study of usually one group of subjects to distinguish the specific and
nonspecific effects of the active treatment. Randomized Study participants are assigned
without bias to particular arms of a study.
- Side Effects
- Unintended, and usually undesirable, reactions that result from a treatment.
- Virus
- A tiny organism that can only grow in the cells of an animal or a person. Several
hundred viruses have been found to cause diseases in people.
1. O'Hara, M., Kiefer, D., Farrell, K., and Kemper, K. "A Review
of 12 Commonly Used Medicinal Herbs." Archives of Family Medicine. 1998.
7(6):523-36.
2. Tyler, V.E. "Milk Thistle." In: The Honest Herbal: A
Sensible Guide to the Use of Herbs and Related Remedies, 3rd ed., edited by M.C.
Smith. Binghamton, NY: Pharmaceutical Products Press, 1993. pp. 209-10.
3. Garciapina, M.P., Perez-Alvarez, V., and Mourelle, M.
"Silymarin Protects Against Paracetamol-Induced Lipid Peroxidation and Liver
Damage." Journal of Applied Toxicology. 1992. 12(6):439-42.
4. Letteron, P., Labbe, G., Degott, C., Berson, A., Fromenty, B.,
Delaforge, M., Larrey, D., and Pessayre, D. "Mechanism for the Protective Effects of
Silymarin Against Carbon Tetrachloride-Induced Liver Peroxidation and Hepatotoxicity in
Mice. Evidence that Silymarin Acts Both as an Inhibitor of Metabolic Activation and as a
Chain-Breaking Antioxidant." Biochemical Pharmacology. 1990. 39(12):2027-34.
5. Davila, J.C., Lenherr, A., and Acosta, D. "Protective Effect
of Flavonoids on Drug-Induced Hepatotoxicity In Vitro." Toxicology.
1989. 57(3):267-86.
6. Ferenci, P., Dragosics, B., Dittrich, H., Frank, H., Benda, L.,
Lochs, H., Meryn, S., Base, W., and Schneider, B. "Randomized Controlled Trial of
Silymarin Treatment in Patients with Cirrhosis of the Liver." Journal of
Hepatology. 1989. 9(1):105-13.
7. Pares, A., Planas, R., Torres, M., Caballeria, J., Viver, J.M.,
Acero, D., Panes, J., Rigau, J., Santos, J., and Rodes, J. "Effects of Silymarin in
Alcoholic Patients with Cirrhosis of the Liver: Results of a Controlled, Double-Blind,
Randomized and Multicenter Trial." Journal of Hepatology. 1998.
28(4):615-21.
8. Buzzelli, G., Moscarella, S., Giusti, A., Duchini, A., Marena,
C., and Lampertico, M. "A Pilot Study of the Liver Protective Effect of
Silybin-Phosphatidylcholine Complex (IdB1016) in Chronic Active Hepatitis." International
Journal of Clinical Pharmacology, Therapy, and Toxicology. 1993. 31(9):456-60.
9. Werbach, M.R. and Murray, M.T. Botanical Influences on
Illness: A Sourcebook of Clinical Research. Tarzana, CA: Third Line Press,
1994.
10. Tyler, V.E. "Licorice." In: The Honest Herbal: A
Sensible Guide to the Use of Herbs and Related Remedies, 3rd ed., edited by M.C.
Smith. Binghamton, NY: Pharmaceutical Products Press, 1993. pp. 197-9.
11. van Rossum, T.G., Vulto, A.G., de Man, R.A., Brouwer, J.T.,
and Schalm, S.W. "Review Article: Glycyrrhizin as a Potential Treatment for Chronic
Hepatitis C." Alimentary Pharmacology and Therapeutics. 1998. 12(3):199-205.
12. Arase, Y., Ikeda, K., Murashima, N., Chayama, K., Tsubota, A.,
Koida, I., Suzuki, Y., Saitoh, S., Kobayashi, M., and Kumada, H. "The Long-Term
Efficacy of Glycyrrhizin in Chronic Hepatitis C Patients." Cancer. 1997.
79(8):1494-500.
13. Abe, Y., Ueda, T., Kato, T., and Kohli, Y.
"Effectiveness of Interferon, Glycyrrhizin Combination Therapy in Patients with
Chronic Hepatitis C." Nippon Rinsho (Japanese Journal of Clinical Medicine).
1994. 52(7):1817-22.
14. Okuno, T., Arai, K., and Shindo, M. "Efficacy of
Interferon Combined Glycyrrhizin Therapy in Patients with Chronic Hepatitis C Resistant to
Interferon Therapy." Nippon Rinsho (Japanese Journal of Clinical Medicine).
1994. 52(7):1823-7.
15. Davydov, V.V., Molokovskii, D.S., and Limarenko, A.I.
"Efficacy of Ginseng Drugs in Experimental Insulin-Dependent Diabetes and Toxic
Hepatitis." Patologicheskaia Fiziologiia i Eksperimentalnaia Terapiia. 1990.
(5):49-52.
16. Jeong, T.C., Kim, H.J., Park, J.I., Ha, C.S., Park, J.D.,
Kim, S.I., and Roh, J.K. "Protective Effects of Red Ginseng Saponins Against Carbon
Tetrachloride-Induced Hepatotoxicity in Sprague Dawley Rats." Planta Medica.
1997. 63(2):136-40.
17. Matsuda, H., Samukawa, K., and Kubo, M.
"Anti-Hepatitic Activity of Ginsenoside Ro." Planta Medica. 1991.
57(6):523-6.
18. Zuin, M., Battezzati, P.M., Camisasca, M., Riebenfeld, D.,
and Podda, M. "Effects of a Preparation Containing a Standardized Ginseng Extract
Combined with Trace Elements and Multivitamins Against Hepatotoxin-Induced Chronic Liver
Disease in the Elderly." Journal of International Medical Research. 1987.
15(5):276-81.
19. Tyler, V.E. "Ginseng and Related Herbs." In: The
Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies, 3rd ed.,
edited by M.C. Smith. Binghamton, NY: Pharmaceutical Products Press, 1993. pp. 153-8.
20. Philipp, M., Kohnen, R., and Hiller, K.O. "Hypericum
Extract Versus Imipramine or Placebo in Patients with Moderate Depression: Randomised
Multicentre Study of Treatment for Eight Weeks." British Medical Journal.
1999. 319(7224):1534-9.
21. National Institutes of Health. Management of Hepatitis C.
NIH Consensus Statement Online. March 24-26, 1997. 15(3):1-41. NIH Consensus Statement No.
5. http://odp.od.nih.gov/consensus/cons/105/105_statement.htm.
The treatments described in this publication are experimental. Researchers have not yet
found out if and how they may be used safely and effectively in most people. If you are
considering any treatment, always first discuss the treatment with your health care
provider.
The term "scientific studies" used in the levels of research refers to
quality research conducted in people by scientists sponsored by the National Center for
Complementary and Alternative Medicine (NCCAM), other Institutes and Centers of the
National Institutes of Health (NIH), and additional biomedical research institutions in
the United States and internationally.
NIH's NCCAM produced this publication to give you information about complementary and
alternative medicine (CAM) practices. The NCCAM is an advocate for quality science,
rigorous and relevant research, and open and objective inquir>
|